Asset
Tildacerfont
Spruce Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04457336 | phase2 | terminated | 2020-08-26 | 2024-02-09 | Spruce Biosciences | A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH |
| NCT04544410 | phase2 | terminated | 2021-02-22 | 2024-10-31 | Spruce Biosciences | A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH |
| NCT05128942 | phase2 | terminated | 2021-12-10 | 2025-01-31 | Spruce Biosciences | A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH |
| NCT05370521 | phase2 | terminated | 2022-05-15 | 2023-08-03 | Spruce Biosciences | A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens |
FDA applications (0)
This company has no applications containing this asset.